Related Content
- Report: Pfizer seeks aid of PBMs in efforts to block generic versions of Lipitor
- Safeway outlines three future growth platforms: Wellness, loyalty and fuel
- CVS Caremark names Helena Foulkes EVP, chief healthcare strategy and marketing officer
- Mike Bloom resigns from CVS/pharmacy, assumes president, COO role at Family Dollar
- Senators look into Pfizer-PBM deal for Lipitor
NEW YORK — According to a Bloomberg report published Friday morning, Abbott Laboratories, Johnson & Johnson and Sanofi are all potential suitors for Bausch & Lomb's eye care business in a deal that could be valued as high as $10 billion.
B&L is being shopped by private equity firm Warburg Pincus, which is working with Goldman Sachs Group, Bloomberg reported, and both Abbott and Sanofi have contracted financial advisors as well.
Other companies who have been invited to bid include Merck and Pfizer.
For the full story, click here.
Find us on Facebook for more information on drug store news, insights and products.

